• Facebook
  • Rss
  • Twitter
  • Youtube
  • Store
  • Donate
NCCS - National Coalition for Cancer Survivorship
  • About
    • Our Mission
    • Our History
    • Our Leadership
      • Policy Advisors
    • Employment
    • Partnerships
    • Financial Information
  • Policy
    • Quality Cancer Care
    • Access to Care
    • Health Equity
    • Redefining Functional Status (RFS)
    • 2020 State of Cancer Survivorship Survey
    • Cancer Care Planning and Communications Act (CCPCA)
  • Get Involved
    • What is Advocacy?
    • Cancer Policy and Advocacy Team (CPAT)
    • Elevating Survivorship
    • Survivor Stories
    • Cancerversary
    • State Based Cancer Advocacy
  • Resources
    • COVID-19 Resources for Cancer Survivors
    • Survivorship Checklist
    • Cancer Survival Toolbox
    • Telehealth
    • Survivorship Champions
    • Publications
      • Talking With Your Doctor
      • Self Advocacy
      • Employment Rights
      • Remaining Hopeful
    • Cancer Convos Podcast
    • Taking Charge of Your Care
    • Care Planning for Cancer Survivors
    • Tools For Care Providers
    • Order Our Resources
  • News
  • Events
    • Ellen L. Stovall Award
      • Nominations
      • Honorees
      • Sponsors
      • Committees
    • From Shadows to Life: A Biography of the Cancer Survivorship Movement
    • Cancer Policy Roundtable
      • Spring 2021 Cancer Policy Roundtable
      • Fall 2020 Cancer Policy Roundtable
      • Spring 2020 Cancer Policy Roundtable
    • Cancer Policy and Advocacy Team (CPAT) Symposium 2020
    • Webinars
  • Contact Us
  • Search
  • Menu Menu
  • 0Shopping Cart

Year-End MATCH (DEADLINE Dec 31): Donate & Make a Difference | Donate

NCCS Starburst 250px

Health Care Roundup: More Drug Pricing News; Clinical Trial Challenges; Trump Promises Action on Surprise Billing; Fake Cancer Cures; More

February 1, 2019/in Cancer News, Cancer Policy Blog Access to Care, Clinical Trials, Drug Pricing, Financial Toxicity, Health Care Coverage, Health Equity Health Care Roundup, NCCS News /by actualize
In order to bring you the latest cancer-related health care policy and news, we at NCCS combined our ACA Updates and What Caught Our Eye (WCOE) content into a weekly email and blog post. We aim to make this a concise, one-stop summary of what you need to know as we continue working together to make cancer care better for everyone.Your feedback is always welcome to make our content more useful to you. Please send comments to feedback@canceradvocacy.org.

Subscribe to our email list and receive these updates in your email box each week »


HEALTH CARE HIGHLIGHTS

Drug Pricing, Drug Pricing, and More Drug Pricing!

This week, the House and Senate held several hearings related to health care, including a House Ways and Means Committee hearing titled “Protecting Americans with Pre-Existing Conditions.” The hearing illustrated the stark difference between the two parties’ health care goals.

There were also dueling drug pricing hearings this week, one from the House Committee on Oversight and Reform titled, “Examining the Actions of Drug Companies Raising Prescription Drug Prices.” The Senate Finance Committee also held a hearing titled, “Drug Pricing in America: A Prescription for Change, Part I.”

Robert Pear of the New York Times provided an overview of the hearings:

Members of Congress from both parties served notice on pharmaceutical companies on Tuesday that the days of unchecked drug-price increases were over and that they would be held politically accountable for exorbitant prices. The new reality became apparent at simultaneous but separate hearings of House and Senate committees where lawmakers said that the relentless increases were unsustainable and unacceptable.

On Thursday, Health and Human Services (HHS) Secretary Alex Azar announced a policy proposal that would eliminate rebates from drug manufacturers to insurers and pharmacy benefit managers in the Medicare program, which the department claims would lower the out-of-pocket spending on prescription drugs at the pharmacy. Azar then called on Congress to pass the proposal into law banning rebates and extending it to the commercial market. Under draft rules, drug manufacturers would be allowed to offer rebates directly to consumers but would no longer be able to give rebates to pharmacy benefit managers. Stay tuned as NCCS analyzes this proposal and its potential impacts on cancer survivors.

NCCS recently commented on another drug pricing proposal by HHS. This proposed rule would change Medicare Part D’s protected classes drug coverage. In response, NCCS joined with other patient and provider groups of the Cancer Leadership Council (CLC) to comment on how these proposed changes could impact patients. The proposed rule would give Medicare plans the option to limit coverage of drugs in six categories, including cancer drugs. In the comment letter, the groups urge HHS to reconsider these changes as they would create barriers to treatments that cancer patients need. One major reservation articulated in the letter concerned the impact of the broader use of prior authorization and step therapy for drugs in protected classes. Access to only one drug in a specific drug class would undermine the ability to receive appropriate and recommended treatment.

https://canceradvocacy.org/policy-comments/nccs-clc-highlight-potential-harm-patients-medicare-part-d-changes/


CHART OF THE WEEK

The Out-of-Pocket Cost Burden for Specialty Drugs in Medicare Part D in 2019

Kaiser Family Foundation

A recent analysis from Kaiser Family Foundation found that despite Medicare’s protections, Part D enrollees with serious health problems can face thousands of dollars in annual out-of-pocket spending.

Support NCCS while shopping on Amazon. A portion of your Amazon purchases will be donated to NCCS when you choose NCCS as your AmazonSmile charity. Get started »

IMPORTANT READS

Clinical Trial Exclusions: Are Researchers Missing Out?

Cure Magazine

Expanding access and increasing recruitment for clinical trials is an ongoing issue for NCCS. This article discusses the many challenges of recruiting patients to participate in clinical trials investigating immunotherapy drugs.

Mohammad Jahanzeb, M.D., a professor of hematology/oncology at the University of Miami Sylvester Comprehensive Cancer Center, says:

At the end of the day, only about 4 percent of the adult population of patients is treated on clinical trials in the United States, as opposed to nearly 90-plus percent of children with cancer.

Read More »

Trump boosts fight against surprise medical bills

The Hill

Momentum is building for action to prevent patients from receiving massive unexpected medical bills, aided by President Trump, who is vowing to take on the issue. Calls for action against so-called "surprise" medical bills have been growing, spurred by viral stories like one involving a teacher in Texas last year who received a $108,000 bill from the hospital after his heart attack.

Read More »

The modern tragedy of fake cancer cures

STAT News

A Jerusalem Post article making the rounds on social media claims that an Israeli biotech company will have “a complete cure for cancer” within a year. Matthew Herper explains why the claim is not true, writing:

The claim, absurd on its face, was particularly frustrating to those who work in medicine and drug development because it seemed so obvious there was not enough evidence to make it.

Read More »

Ads for Short-Term Plans Lacking ACA Protections Swamped Consumers’ Online Searches

Kaiser Health News

A new study shows that consumers looking for health insurance online last fall — using search terms such as “Obamacare plans,” “ACA enroll” and “cheap health insurance” — were most often directed to websites that sell short-term limited duration health plans that don’t comply with the ACA’s consumer protections.

Read More »

Consolidation of health insurance and drug benefits is back

Axios

Through rapid consolidation, five companies – Anthem, Cigna, CVS Health, Humana and UnitedHealth – will control insurance and pharmacy benefits for more than 125 million Americans.

Read More »


Related Posts

https://canceradvocacy.org/blog/health-care-roundup-jan-25-2019/

https://canceradvocacy.org/policy-comments/nccs-clc-highlight-potential-harm-patients-medicare-part-d-changes/

Tags: clinical trials, drug pricing, financial issues, health care roundup, Medicare, What Caught Our Eye
Share this entry
  • Share on Facebook
  • Share on Twitter
https://canceradvocacy.org/wp-content/uploads/2017/01/NCCS-Starburst-250px.png 250 250 actualize https://canceradvocacy.org/wp-content/uploads/2020/06/NCCA-Logo.png actualize2019-02-01 16:02:532019-02-01 16:02:53Health Care Roundup: More Drug Pricing News; Clinical Trial Challenges; Trump Promises Action on Surprise Billing; Fake Cancer Cures; More
You might also like
FacebookProfile3 CMS offers new guidance to help lower income Americans obtain affordable, comprehensive coverage
HHS Humphrey bldg 1200 800x400 How to Voice Opposition to the Proposed Rule for Short-Term Limited Duration Coverage
NCCS Starburst 250px What Caught Our Eye: Trump Acts to Undermine ACA; Susan Gubar Reviews ‘Cancer Humor’ Books; Life After Cancer; and More
NCCS Starburst Thumbnail WCOE: Shared Decision-Making, Medicare Plans to Pay Doctors to Talk About End-of-Life Care, and Patient Advocate Meets with Congressional Representative
NCCS Starburst 250px What Caught Our Eye: ACA Analysis/Debate, Doc/Patient Communication, Universal Cancer Care, Financial Toxicity, Palliative Care Pain Studies
NCCS Starburst Thumbnail NCCS CEO’s Article via CURE “Aiming to Improve Quality of Cancer Care”
NCCS Starburst 250px Health Care Roundup: New Health Care Bills; NCCS Co-Founder Susie Leigh on Life After Cancer; Oncology Care Model; Racial Disparities; More
NCCS Starburst 250px Health Care Roundup: Association Health Plans and ACA Repeal; Benefits of Exercise for Childhood Survivors; NIH Grant System; and More

Latest News

NCCS Founders at 1990 Assembly

The Birth of the Cancer Survivorship Movement and How It Transformed Cancer Care for Millions

March 25, 2021
Guest Post by Judith L. Pearson Best-Selling Author of From Shadows to Life: A Biography…
Read more
https://canceradvocacy.org/wp-content/uploads/2018/02/10-Founders-1990-NCCS-Assembly.jpg 600 1200 NCCS Staff https://canceradvocacy.org/wp-content/uploads/2020/06/NCCA-Logo.png NCCS Staff2021-03-25 10:36:202021-03-25 13:46:05The Birth of the Cancer Survivorship Movement and How It Transformed Cancer Care for Millions
HHS Humphrey bldg 1200

Biden Rescinds Trump Admin Proposal to Limit Medicare Part D Coverage of Drugs in “Six Protected Classes”

March 19, 2021
This week, the Biden administration rescinded a Trump administration-proposed plan…
Read more
https://canceradvocacy.org/wp-content/uploads/2017/10/HHS-Humphrey-bldg-1200.jpg 600 1200 NCCS Staff https://canceradvocacy.org/wp-content/uploads/2020/06/NCCA-Logo.png NCCS Staff2021-03-19 13:36:192021-03-23 14:46:18Biden Rescinds Trump Admin Proposal to Limit Medicare Part D Coverage of Drugs in “Six Protected Classes”
CDC Headquarters

NCCS Recommends That States Allocate COVID-19 Vaccines to Cancer Care Providers

March 1, 2021
The National Coalition for Cancer Survivorship (NCCS) and the Cancer Leadership Council…
Read more
https://canceradvocacy.org/wp-content/uploads/CDC_Headquarters_PHIL_pubdomain_1200.jpg 600 1200 NCCS Staff https://canceradvocacy.org/wp-content/uploads/2020/06/NCCA-Logo.png NCCS Staff2021-03-01 15:49:432021-03-04 17:45:07NCCS Recommends That States Allocate COVID-19 Vaccines to Cancer Care Providers

Take Action

Stovall Award

The Ellen L. Stovall Award for Innovation in Patient-Centered Cancer Care is a unique opportunity for patients and survivors to recognize pioneers who are transforming the cancer care system.

Join CPAT

The NCCS Cancer Policy & Advocacy Team (CPAT) is a program for survivors and caregivers to learn about pressing policy issues that affect quality cancer care in order to be engaged as advocates in public policy around the needs of cancer survivors.

Share Your Story

NCCS represents the millions of Americans who share a common experience – the survivorship experience – living with, through and beyond a cancer diagnosis.

STAY CONNECTED

Together we can improve cancer care for survivors! Sign up to be the first to know about cancer policy issues and ways to take action

  • About
    • Our Mission
    • Our History
    • Our Leadership
      • Policy Advisors
    • Employment
    • Partnerships
    • Financial Information
  • Policy
    • Quality Cancer Care
    • Access to Care
    • Health Equity
    • Redefining Functional Status (RFS)
    • 2020 State of Cancer Survivorship Survey
    • Cancer Care Planning and Communications Act (CCPCA)
  • Get Involved
    • What is Advocacy?
    • Cancer Policy and Advocacy Team (CPAT)
    • Elevating Survivorship
    • Survivor Stories
    • Cancerversary
    • State Based Cancer Advocacy
  • Resources
    • COVID-19 Resources for Cancer Survivors
    • Survivorship Checklist
    • Cancer Survival Toolbox
    • Telehealth
    • Survivorship Champions
    • Publications
      • Talking With Your Doctor
      • Self Advocacy
      • Employment Rights
      • Remaining Hopeful
    • Cancer Convos Podcast
    • Taking Charge of Your Care
    • Care Planning for Cancer Survivors
    • Tools For Care Providers
    • Order Our Resources
  • News
  • Events
    • Ellen L. Stovall Award
      • Nominations
      • Honorees
      • Sponsors
      • Committees
    • From Shadows to Life: A Biography of the Cancer Survivorship Movement
    • Cancer Policy Roundtable
      • Spring 2021 Cancer Policy Roundtable
      • Fall 2020 Cancer Policy Roundtable
      • Spring 2020 Cancer Policy Roundtable
    • Cancer Policy and Advocacy Team (CPAT) Symposium 2020
    • Webinars
  • Contact Us

National Coalition for Cancer Survivorship
8455 Colesville Road  |  Suite 930  |  Silver Spring, MD 20910
877-NCCS-YES  |  info@canceradvocacy.org
Privacy Policy  |  Terms and Conditions

Copyright © 1995-2021 by the National Coalition for Cancer Survivorship
National Coalition for Cancer Survivorship, NCCS, Cancer Survival Toolbox, and related Logos are registered in the United States as trademarks of the National Coalition for Cancer Survivorship.

NCCS and Cancer Leadership Council Highlight Potential Harm to Patients of Proposed... NCCS Policy Comments HHS bldg NCCS Starburst 250px Health Care Roundup: Drug Pricing; Cancer Deaths Rise Globally; Health Care...
Scroll to top

Harmar Brereton, MD

Founder
Northeast Regional Cancer Institute

 

“Perhaps one of the most impactful collaborations in Dr. Brereton’s extraordinary career remains his early work and long friendship with Ellen Stovall. Through him, and in turn through the thousands of lives he has touched, Ellen’s work continues, and her mission lives on.”

—Karen M. Saunders
President, Northeast Regional Cancer Institute